Haleon Raising Stake in Tianjin TSKF Pharmaceutical JV to 88%

MT Newswires09-30

London and New York-listed Sensodyne maker Haleon agreed to acquire an additional 33% equity interest in Tianjin TSKF Pharmaceutical from joint venture partners Tianjin Pharmaceutical Group and Tianjin Pharmaceutical Da Ren Tang Group (SHA:600329, SGX:T14).

Total consideration for the stake acquisition is 4.47 billion yuan, according to a Sept. 27 press release.

The deal will increase Haleon's equity interest in Tianjin TSKF Pharmaceutical to 88% from 55%.

Also, Haleon secured an option to acquire Tianjin Pharmaceutical Da Ren Tang Group's remaining 12% shareholding in Tianjin TSKF Pharmaceutical.

Tianjin TSKF Pharmaceutical manufactures and distributes brands such as Fenbid, Voltaren and Bactroban.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2471810696?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2024-09-30 11:22","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2471810696","market":"sg","top_or_hot":-1,"title":"Haleon Raising Stake in Tianjin TSKF Pharmaceutical JV to 88%","media":"MT Newswires","content":"<html><body><p> London and New York-listed Sensodyne maker <a href=\"https://laohu8.com/S/HLN\">Haleon</a> agreed to acquire an additional 33% equity interest in Tianjin TSKF Pharmaceutical from joint venture partners Tianjin Pharmaceutical Group and Tianjin Pharmaceutical Da Ren Tang Group (SHA:600329, SGX:T14).</p><p>Total consideration for the stake acquisition is 4.47 billion yuan, according to a Sept. 27 press release.</p><p>The deal will increase Haleon's equity interest in Tianjin TSKF Pharmaceutical to 88% from 55%.</p><p>Also, Haleon secured an option to acquire Tianjin Pharmaceutical Da Ren Tang Group's remaining 12% shareholding in Tianjin TSKF Pharmaceutical.</p><p>Tianjin TSKF Pharmaceutical manufactures and distributes brands such as Fenbid, Voltaren and Bactroban.</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Haleon Raising Stake in Tianjin TSKF Pharmaceutical JV to 88%</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nHaleon Raising Stake in Tianjin TSKF Pharmaceutical JV to 88%\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-09-30 11:22 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.mtnewswires.com/><strong>MT Newswires</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>London and New York-listed Sensodyne maker Haleon agreed to acquire an additional 33% equity interest in Tianjin TSKF Pharmaceutical from joint venture partners Tianjin Pharmaceutical Group and ...</p>\n\n<a href=\"https://www.mtnewswires.com/\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK0060","symbol_name":"抗癌","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2471810696","we_media_id":"1060499803","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2471810696","pubTimestamp":1727666529,"sourceInfo":null,"weMediaInfo":{"media_name":"MT Newswires","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1060499803","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"London and New York-listed Sensodyne maker Haleon agreed to acquire an additional 33% equity interest in Tianjin TSKF Pharmaceutical from joint venture partners Tianjin Pharmaceutical Group and Tianji","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"600329":"达仁堂","BK0060":"抗癌","BK6506":"制药与医学研究概念","BK6079":"制药","BK0239":"医药制造","T14.SI":"达仁堂","BK0164":"国企混改","BK0188":"融资融券","BK0028":"国家队"},"translate_title":"Haleon将天津TSKF制药合资企业的股份增至88%","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"600329":0.9,"T14.SI":0.9},"content_text":"London and New York-listed Sensodyne maker Haleon agreed to acquire an additional 33% equity interest in Tianjin TSKF Pharmaceutical from joint venture partners Tianjin Pharmaceutical Group and Tianjin Pharmaceutical Da Ren Tang Group (SHA:600329, SGX:T14).Total consideration for the stake acquisition is 4.47 billion yuan, according to a Sept. 27 press release.The deal will increase Haleon's equity interest in Tianjin TSKF Pharmaceutical to 88% from 55%.Also, Haleon secured an option to acquire Tianjin Pharmaceutical Da Ren Tang Group's remaining 12% shareholding in Tianjin TSKF Pharmaceutical.Tianjin TSKF Pharmaceutical manufactures and distributes brands such as Fenbid, Voltaren and Bactroban.","kind":null,"is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.1","shortVersion":"4.29.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2471810696"}